Literature DB >> 23611259

Targeting melanoma by small molecules: challenges ahead.

Rizwan Haq1, David E Fisher.   

Abstract

Significant progress has been made in targeting melanoma using small molecule inhibitors, but challenges remain. Here we describe the history of screening approaches in melanoma and their limitations. We propose several approaches to refine our screening models to enhance the discovery process. It is hoped that this discussion will stimulate further improvements in our development of small molecules inhibitors for treatment of melanoma patients.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23611259      PMCID: PMC3971475          DOI: 10.1111/pcmr.12109

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  65 in total

Review 1.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

Review 2.  Therapeutic selectivity and the multi-node drug target.

Authors:  Joseph Lehar; Andrew S Krueger; Grant R Zimmermann; Alexis A Borisy
Journal:  Discov Med       Date:  2009-12       Impact factor: 2.970

3.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

4.  Direct inhibition of the NOTCH transcription factor complex.

Authors:  Raymond E Moellering; Melanie Cornejo; Tina N Davis; Cristina Del Bianco; Jon C Aster; Stephen C Blacklow; Andrew L Kung; D Gary Gilliland; Gregory L Verdine; James E Bradner
Journal:  Nature       Date:  2009-11-12       Impact factor: 49.962

5.  Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Authors:  Sonja J Heidorn; Carla Milagre; Steven Whittaker; Arnaud Nourry; Ion Niculescu-Duvas; Nathalie Dhomen; Jahan Hussain; Jorge S Reis-Filho; Caroline J Springer; Catrin Pritchard; Richard Marais
Journal:  Cell       Date:  2010-01-22       Impact factor: 41.582

6.  Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.

Authors:  Claudia Scholl; Stefan Fröhling; Ian F Dunn; Anna C Schinzel; David A Barbie; So Young Kim; Serena J Silver; Pablo Tamayo; Raymond C Wadlow; Sridhar Ramaswamy; Konstanze Döhner; Lars Bullinger; Peter Sandy; Jesse S Boehm; David E Root; Tyler Jacks; William C Hahn; D Gary Gilliland
Journal:  Cell       Date:  2009-05-29       Impact factor: 41.582

7.  Identification of selective inhibitors of cancer stem cells by high-throughput screening.

Authors:  Piyush B Gupta; Tamer T Onder; Robert A Weinberg; Eric S Lander; Guozhi Jiang; Kai Tao; Charlotte Kuperwasser
Journal:  Cell       Date:  2009-08-13       Impact factor: 41.582

8.  A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.

Authors:  Satoru Yokoyama; Susan L Woods; Glen M Boyle; Lauren G Aoude; Stuart MacGregor; Victoria Zismann; Michael Gartside; Anne E Cust; Rizwan Haq; Mark Harland; John C Taylor; David L Duffy; Kelly Holohan; Ken Dutton-Regester; Jane M Palmer; Vanessa Bonazzi; Mitchell S Stark; Judith Symmons; Matthew H Law; Christopher Schmidt; Cathy Lanagan; Linda O'Connor; Elizabeth A Holland; Helen Schmid; Judith A Maskiell; Jodie Jetann; Megan Ferguson; Mark A Jenkins; Richard F Kefford; Graham G Giles; Bruce K Armstrong; Joanne F Aitken; John L Hopper; David C Whiteman; Paul D Pharoah; Douglas F Easton; Alison M Dunning; Julia A Newton-Bishop; Grant W Montgomery; Nicholas G Martin; Graham J Mann; D Timothy Bishop; Hensin Tsao; Jeffrey M Trent; David E Fisher; Nicholas K Hayward; Kevin M Brown
Journal:  Nature       Date:  2011-11-13       Impact factor: 49.962

9.  Systematic identification of genomic markers of drug sensitivity in cancer cells.

Authors:  Mathew J Garnett; Elena J Edelman; Sonja J Heidorn; Chris D Greenman; Anahita Dastur; King Wai Lau; Patricia Greninger; I Richard Thompson; Xi Luo; Jorge Soares; Qingsong Liu; Francesco Iorio; Didier Surdez; Li Chen; Randy J Milano; Graham R Bignell; Ah T Tam; Helen Davies; Jesse A Stevenson; Syd Barthorpe; Stephen R Lutz; Fiona Kogera; Karl Lawrence; Anne McLaren-Douglas; Xeni Mitropoulos; Tatiana Mironenko; Helen Thi; Laura Richardson; Wenjun Zhou; Frances Jewitt; Tinghu Zhang; Patrick O'Brien; Jessica L Boisvert; Stacey Price; Wooyoung Hur; Wanjuan Yang; Xianming Deng; Adam Butler; Hwan Geun Choi; Jae Won Chang; Jose Baselga; Ivan Stamenkovic; Jeffrey A Engelman; Sreenath V Sharma; Olivier Delattre; Julio Saez-Rodriguez; Nathanael S Gray; Jeffrey Settleman; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Sridhar Ramaswamy; Ultan McDermott; Cyril H Benes
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

10.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

View more
  7 in total

1.  Genotyping of cutaneous melanoma.

Authors:  Isabella C Glitza; Michael A Davies
Journal:  Chin Clin Oncol       Date:  2014-09

Review 2.  Pro-survival role of MITF in melanoma.

Authors:  Mariusz L Hartman; Malgorzata Czyz
Journal:  J Invest Dermatol       Date:  2014-08-21       Impact factor: 8.551

3.  Harnessing the polyamine transport system to treat BRAF inhibitor-resistant melanoma.

Authors:  Eric T Alexander; Olivia El Naggar; Erin Fahey; Kelsey Mariner; Julia Donnelly; Katelyn Wolfgang; Otto Phanstiel; Susan K Gilmour
Journal:  Cancer Biol Ther       Date:  2021-02-18       Impact factor: 4.742

Review 4.  MITF in melanoma: mechanisms behind its expression and activity.

Authors:  Mariusz L Hartman; Malgorzata Czyz
Journal:  Cell Mol Life Sci       Date:  2014-11-30       Impact factor: 9.261

5.  A Novel Polyamine-Targeted Therapy for BRAF Mutant Melanoma Tumors.

Authors:  Molly C Peters; Allyson Minton; Otto Phanstiel Iv; Susan K Gilmour
Journal:  Med Sci (Basel)       Date:  2018-01-05

6.  Vanillin Suppresses Cell Motility by Inhibiting STAT3-Mediated HIF-1α mRNA Expression in Malignant Melanoma Cells.

Authors:  Eun-Ji Park; Yoon-Mi Lee; Taek-In Oh; Byeong Mo Kim; Beong-Ou Lim; Ji-Hong Lim
Journal:  Int J Mol Sci       Date:  2017-03-01       Impact factor: 5.923

7.  Nuclear Entry of CRTC1 as Druggable Target of Acquired Pigmentary Disorder.

Authors:  Cheong-Yong Yun; Seung Deok Hong; Young Hee Lee; Jiyeon Lee; Da-Eun Jung; Ga Hyun Kim; Song-Hee Kim; Jae-Kyung Jung; Ki Ho Kim; Heesoon Lee; Jin Tae Hong; Sang-Bae Han; Youngsoo Kim
Journal:  Theranostics       Date:  2019-01-21       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.